Impact ledger
Theravance Biopharma, Inc. (TBPH): the developments shaping its investment case
Follow the evidence affecting Theravance Biopharma, Inc.'s demand outlook, valuation assumptions. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Test assumptions, examine opportunities, and save your research.
Material developments
Evidence affecting valuation assumptions
Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.
| Date | Assumption | Direction | Interpretation |
|---|---|---|---|
| 2026-08-10 | revenue | Bullish | High confidence in achieving the $100 million 2026 milestone payment from Royalty Pharma based on TRELEGY global net sales. |
| 2026-06-29 | multiple | Bullish | Target re-rates to bid premium until close. |
Event impact log
2 events mapped to TBPH since 2026-08-21. Evidence through 2026-09-10.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-10 | Theravance Biopharma, Inc. provides update on litigation related to Zymeworks Inc. merger | Direct impact on merger completion probability and potential legal costs. | Bearish | 1-3m | 0.70 |
| 2026-08-21 | Zymeworks Inc. to Acquire Theravance Biopharma, Inc. for $17.00 Per Share Plus CVR | Direct acquisition of the company at a premium to its pre-announcement trading price. | Bullish | intraday | 0.90 |
Continue this research
Build your Theravance Biopharma, Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the TBPH entity page →